Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 57 for “"progression-free survival"”.
-
Dysphagia progression-free survival in patients with locally advanced and metastatic oesophageal cancer receiving palliative radiation therapy
… aim of this study was to determine the dysphagia progression-free survival (DPFS) in patients with advanced oesophageal carcinoma treated with palliative radiotherapy (RT). Methods: The medical records of all patients with oesophageal carcinoma presenting to Groote Schuur Hospital, Cape Town …
-
Prostate-specific Antigen Nadir and Time to Prostate-specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict the Prognosis in Patients with Metastatic Prostate Cancer
… maximal androgen blockade (MAB) on the disease progression and cancer-specific survival in patients with metastatic, hormone sensitive prostate cancer. MATERIALS AND METHODS: One hundred thirty-one patients with metastatic, hormone sensitive prostate cancer treated with MAB at our institution …
-
The impact of cholesterol and its metabolites on the ovarian tumor microenvironment and cancer progression
… to be clinically important for ovarian cancer survival, highlighting it and its metabolism as potential therapeutic targets for improving the lifespan of patients. In a cohort of 153 patients, we found high total, LDL or non-HDL cholesterol was associated with high tumor grade, which in turn …
-
Cirkuliuojančių prostatos vėžio imuninių veiksnių prognostinis vaidmuo /
… molecules may provide new insights into disease progression and prognosis. The main aim of this study was to evaluate the prognostic value of circulating sPD-1, sPD-L1 and immune parameters in prostate cancer patients. The goals of the study were to determine the changes in sPD-1 and sPD-L1 …
-
Prevalence of Pik3ca-Mutations and Response to First-Line Endocrine Therapy in a Population of Bulgarian Patients with HR(+) HER2(–) Metastatic Breast Cancer // Честотата на PIK3CA-мутацията и отговорът към първа линия ендокринна терапия в популацията от български пациентки с HR(+)HER2(-) метастазирал карцином на гърдата
… a statistically significant difference in median progression-free survival and OS in first-line therapy with ET±CDK4/6 inhibitor in patients with confirmed PIK3CA mutation and those without mutation.
-
Is SABR cost-effective in oligometastatic cancer? An economic analysis of SABR-COMET randomized trial
… was associated with an improvement in both progression-free survival and overall survival compared to standard of care (SoC). SABR, however, is associated with higher costs and treatment-related toxicity. The objective of this study was to assess the cost-effectiveness of SABR versus SoC in …
-
Imaging Biomarkers of Response to Immune Checkpoint Inhibition in Melanoma
… melanoma demonstrated significantly increased progression-free survival, there is an unmet need for clinical decision-making tools that can be used for monitoring the efficacy of these costly agents, their potential side effects and the identification of patients with the most suitable …
-
Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing
… trough imatinib levels, experienced improved progression-free survival similar to that of <em>KIT </em>exon 11 patients.</p> <p>Therefore, we have found that imatinib plasma levels were higher in patients with elevated Aspartate amino transferase, were women, were older, or were being treated …
-
TRATTAMENTO DEL NSCLC EGFR-MUTATO LOCALMENTE AVANZATO MEDIANTE ASSOCIAZIONE DI ERLOTINIB E RADIOTERAPIA
… proseguito il trattamento con Erlotinib fino a progressione, con rivalutazione strumentale ogni 3 mesi. Risultati: al termine dello studio, a settembre 2013, dopo un follow-up mediano di 21 mesi (range 5-34 mesi), 9 pazienti stanno proseguendo il trattamento, fino ad eventuale progressione. Dei …
-
Comparison of Survival between Patients with Serous Fallopian Tube carcinoma and Serous Adenocarcinoma of the Ovary
… had no enough evidence. So we sought to compare survival trends between fallopian tube carcinoma and ovarian carcinoma patients in a matched, case–control comparison. Fifteen patients with serous fallopian tubal carcinoma were identified on Ajou university medical center from September 1994 to …
-
EFFECTS OF LEPTIN ON ESTABLISHED GLIOBLASTOMA CELL LINES
… studies examining the role of stress in cancer progression. In animal models, eustress appears to slow tumor growth and recurrence resulting in increased overall survival and progression free survival while distress is associated with decreased overall survival. The cellular pathways activated …
-
Role of C-Met and Egfr In Acquired Resistance to Parp Inhibitors In Triple-Negative Breast Cancer
… rates of ~60%, the prolongation in median progression-free survival with PARP inhibitors is modest, suggesting the emergence of resistance. We previously demonstrated that c-MET contributes to intrinsic resistance to PARP inhibitors in triple-negative breast cancer. However, whether c-MET …
-
Computational imaging and multiomic biomarkers for precision medicine: characterizing heterogeneity in lung cancer.
… status, to enhance the ability to predict progression-free survival in a preliminary cohort of patients with stage 4 NSCLC, treated with first-line anti-PD1/PDL1 checkpoint inhibitor therapy PEMBROLIZUMAB. This study also showed that mitigation of the heterogeneity introduced by voxel …
-
Evaluation of prognostic risk factors at diagnosis and treatment outcomes in adult patients with early-stage hodgkin lymphoma in Cape Town, South Africa
… II unfavourable disease. The 5-year overall survival for the favorable and unfavourable groups was similar (94% vs. 90%, P=0.599). Progression free survival at 5 years was also similar (83% vs. 88%, P=0.984). This study demonstrates excellent 5-year survival outcomes in early-stage cHL …
-
Ependymal tumours in childhood: outcomes and prognostic factors
… chemotherapy. RESULTS: The 5-year overall survival (OS) was 63,3 % (median follow up of 46 months). The 5 year progression free survival (PFS) was 50,70%. Seventeen (33,3%) patients experienced treatment failure, of which 13 (76,5%) represented local failure. The median time to first …
-
Advanced breast cancer: A retrospective review comparing two palliative radiotherapy protocols used at Groote Schuur Hospital between 2010 and 2013
… evaluate and compare the loco-regional progression free survival (PFS), overall survival (OS) and acute effects of the two breast palliative regimes used in patients with locally advanced or metastatic breast cancer between 2010 and 2013 in a single institution. Methods: Compliance to …
-
Molecular Determinants of Residual Disease In Ovarian Cancer
… surgery is associated with adverse overall and progression-free survival as well as poor response to adjuvant chemotherapy. Accurate identification of patients at high risk of residual disease will help avoid unnecessary surgeries and help in triaging these patients to neoadjuvant chemotherapy …
-
Valutazione della terapia chirurgica con resezione e ricostruzione vascolare e della terapia oncologica nei carcinomi della tiroide localmente avanzati
… statisticamente significativa solo tra la PFS (Progression Free Survival) del braccio di controllo e quella del braccio sperimentale a favore del braccio sperimentale (p=0.0399), ma osservando la sopravvivenza globale a 18 mesi non vi è differenza statisticamente significativa (p=0.197). …
-
Hypoxia Activated Prodrug and Anti-Angiogenic Therapy Cooperate to Treat Pancreatic Cancer But Elicit Immune Suppressive G-Mdsc Infiltration
… ICB refractory patients showed prolonged progression free survival. While these studies highlight hypoxia as therapeutically tractable, we lack a complete understanding of the contribution of the tumor vasculature to hypoxia reduction therapy, as well as the downstream consequences of …
Page 1 of 3